Norursodeoxycholic Acid vs. Placebo in NASH

Inclusion Criteria: * Must be willing to participate in the study and provide written informed consent * Male or female patients ≥ 18 and \< 75 years * Centrally assessed histological evidence of NASH and liver fibrosis * Women of childbearing potential agree to use a highly effective method of birth control during the entire duration of the trial and for 4 weeks following the last dose of trial treatment Exclusion Criteria: * Patients taking prohibited medications * Presence of liver cirrhosis * Type 1 diabetes or uncontrolled Type 2 diabetes * History or presence of any other significant concomitant liver diseases * History of liver transplantation * BMI \>45 kg/m\^2 * Any known relevant infectious disease (e.g., active tuberculosis, acquired immunodeficiency syndrome \[AIDS\]-defining diseases) * Abnormal renal function (glomerular filtration rate estimated from cystatin C \< 30 ml/min) at screening visit * Any active malignant disease (except for basal cell carcinoma) * Existing or intended pregnancy or breast-feeding